Far question but if you reread 18 Oct 2023 release carefully you'll note this wording: "iPPS is reversing the breakdown of cartilage at 6 months". The good news also is twice weekly dosage is consistent and superior overall and on each Compartment/Region
However, the way this data is more likely to be positioned with the regulatory authorities is to suggest it's slowing the inevitable progression of OA.
Why pharma aren't jumping all over this is the $B question we're all now asking ourselves.
Far question but if you reread 18 Oct 2023 release carefully...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $85.7M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 24.5¢ | 24.5¢ | $31.10K | 126.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 146333 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 50464 | 4 |
View Market Depth
| Last trade - 16.10pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
25.0¢ |
Change
0.000 ( 2.04 %) |
||||
| Open | High | Low | Volume | ||
| 24.5¢ | 25.0¢ | 24.5¢ | 58268 | ||
| Last updated 15.27pm 07/06/2024 ? | |||||
| PAR (ASX) Chart |